Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

Published Date: 02 Feb 2024

Pembrolizumab improves OS, while nivolumab as a single agent has no effect on DFS.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

2.

BlurryScope: A compact, AI-powered microscope for rapid, cost-effective cancer scoring

3.

Telemedicine services linked to reducing excess mortality

4.

It Is Cancer in Kate Middleton.

5.

Oncology Drug Shortages Persist, but Continue to Evolve


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot